We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX.
- Authors
Soumerai, J.; Wang, L.; Gu, F.; Gu, T.; Liu, F. F.
- Abstract
REAL-WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX B Introduction: b Despite recent therapeutic advances, in particular the development and regulatory approvals of BTKi and venetoclax, current therapies are not curative in CLL/SLL, and evidence remains limited regarding outcomes of pts with R/R CLL/SLL previously treated with both BTKi and venetoclax. Pts in the BTKi progression/venetoclax failure (DF) group received >=2 prior lines of therapy (LOT) with progressive disease (PD) while on a BTKi and either no objective response, PD, or intolerance with venetoclax.
- Subjects
BRUTON tyrosine kinase; PROTEIN-tyrosine kinase inhibitors; CHRONIC lymphocytic leukemia; VENETOCLAX; RICHTER syndrome; FLUDARABINE
- Publication
Hematological Oncology, 2023, Vol 41, p733
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_586